Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

JPM26: Eli Lilly’s obesity drugs target commercial and governmental access

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.

Latest news

JPM26: Jazz sells PRV for $200m, targets deals in 2026

The sale price marks an inflection in voucher market value over recent years.

JPM26: Bi- and multispecific modalities power Wuxi Biologics growth

Presenting at the conference, Dr Chen discussed their highly integrated and holistic CDRMO+ platform.

JPM26: Fujifilm’s modular manufacturing answer to pharma tariffs

The ‘KojoX’ method of cloning facilities around the globe keeps the CDMO agile in an industry fractured by geopolitical strife.

Novo Nordisk Foundation pours $850m into European life sciences economy

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China and the US.

FDA and EMA release collaborative AI framework for drug development

The joint guidance was created to ensure drug developers employ best practices when using AI.

Big pharma and investors re-engage in CGTs and race to scale

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.